logo
Share SHARE
FONT-SIZE Plus   Neg

Actavis Reaches Deal With Purdue Pharma To Settle Patent Litigation On OxyContin

Actavis Inc. (ACT) announced that it has entered into an agreement with Purdue Pharma to settle all outstanding patent litigation related to Actavis' generic version of the currently marketed abuse-deterrent formulation of OxyContin.

As per the terms of the agreement, Actavis will be licensed to market a specified number of bottles of its generic OxyContin beginning on January 1, 2014. Launch of Actavis' product is contingent upon the Company receiving final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for generic OxyContin.

Alternatively, if Actavis is unable to gain FDA approval of its generic OxyContin prior to September 1, 2014, the company will be permitted to launch a specified number of bottles of an authorized generic version of Purdue's abuse-deterrent product beginning in October 2014.

Actavis anticipates that the agreement will represent more than $100 million in combined gross profit in 2014 and 2015, more heavily weighted to 2014. The agreement is expected to result in a more modest contribution from 2016 through 2019. Other terms of the settlement were not disclosed.

OxyContin had U.S. sales of approximately $2.8 billion for the twelve month period ending January 31, 2013 according to IMS Health.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Consumer Financial Protection Bureau or CFPB filed a lawsuit Wednesday against Navient, the nation's largest student loan company, alleging that it failed borrowers at at every stage of repayment. In response, Navient, in a statement, said the allegations are unfounded, and with political motivations, and rejected CFPB ultimatum to settle by Inauguration Day or be sued. Lilly is all set to acquire CoLucid Pharma for $46.50 per share in cash or approximately $960 million. Shares of Netflix Inc. (NFLX), Monday gained over 8 percent in extended trading session after the online-video streaming service reported a fourth-quarter profit that trumped analysts estimates, driven largely by higher-than-expected subscriber additions both domestically and internationally. Netflix...
comments powered by Disqus
Follow RTT